CREATE Medicines Doses First Patient in Phase 1/2 Trial of MT-304, Advancing In Vivo Multi-Immune CAR Therapy

Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordin...

April 28, 2026 | Tuesday | News
Santhera Pharmaceuticals Wins Positive CHMP Opinion to Expand AGAMREE® Use to Younger Duchenne Patients

Santhera Pharmaceuticals (SIX: SANN)  announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA...

April 28, 2026 | Tuesday | News
Novartis Secures EU Approval for Rhapsido® (Remibrutinib), First Oral Targeted Therapy for Chronic Spontaneous Urticaria

Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies ...

April 28, 2026 | Tuesday | News
Mabwell Advances First Nectin-4 ADC into Phase III for TNBC with 9MW2821

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clini...

April 27, 2026 | Monday | News
Repertoire Immune Medicines Doses First Patient in Phase 1/2 Trial of Novel TCR Bispecific RPTR-1-201 for Solid Tumors

Clinical trial will evaluate safety, tolerability and antitumor activity of Repertoire's novel off-the-shelf T cell receptor (TCR) bispecific therapy as ...

April 27, 2026 | Monday | News
From Promise to Practice: Lance Alstodt on Advancing Scalable Stem Cell Therapies at BioRestorative Therapies, Inc.

Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative The...

April 27, 2026 | Monday | Interaction
Specialised Therapeutics Secures Australia and Singapore Approval for ZEPZELCA–Tecentriq in ES-SCLC

  ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-...

April 22, 2026 | Wednesday | News
Immatics’ PRAME-Directed TCR T-Cell Therapy Drives Deep Remission in Pediatric Solid Tumor Case

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...

April 21, 2026 | Tuesday | News
Sanofi’s Nuvaxovid Shows Superior Tolerability vs mNEXSPIKE in Head-to-Head Study

Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase...

April 21, 2026 | Tuesday | Reports
KIMMTRAK Doubles Five-Year Survival in First-Line Metastatic Uveal Melanoma

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed ac...

April 21, 2026 | Tuesday | News
Making Nucleic Acid Therapeutics Manufacturing More Sustainable at Scale

The demand for nucleic acid therapeutics (NATs) is rapidly altering the therapeutic landscape across a wide range of diseases. Recent industry data highlig...

April 20, 2026 | Monday | Expert Opinion
PRAME-Targeted TCR T-Cell Therapy Drives Deep Remission in Pediatric Cancer Case

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...

April 20, 2026 | Monday | News
MiNK’s agenT-797 Combination Delivers 77% Disease Control Rate in Gastroesophageal Cancer Study

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and l...

April 20, 2026 | Monday | News
PacBio and Covaris Unveil Integrated Workflow to Unlock HiFi Sequencing from FFPE Tumor Samples

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample...

April 17, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close